Sign in
TerminatedPhase 4

The Effect of NAC on Lung Function and CT Mucus Score

Key facts

Who runs it
University of California, San Francisco
Where
San Francisco, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 4
People taking part
4 people enrolled
Started
20 Feb 2019
Ended
21 Feb 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • n-acetylcystine + albuterol
  • 0.9% saline + albuterol
Record updated
11 June 2026
Why it stopped
The study was terminated due to COVID restrictions and funding challenges. The study was then simplified and redesigned as the TEAM study (NCT06152653).

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (19)Hide the full registry criteria

Who can take part

  • Male or female between the ages of 18 and 80 years of age at Visit 1
  • Written informed consent obtained from subject and ability for subject to comply with the requirements of the study
  • Able to perform reproducible spirometry according to American Thoracic Society (ATS) criteria
  • Physiological evidence of airflow obstruction (FEV1 bronchodilator reversibility of ≥ 12% or hyperreactivity to methacholine reflected by a methacholine provocative concentration that results in a 20% fall in FEV1(PC20) ≤ 16 mg/mL)
  • Clinical history of asthma per patient report or medical record
  • Pre-bronchodilator FEV1 > 35% predicted
  • Post-bronchodilator FEV1 > 40% but < 90% predicted
  • Asthma requiring treatment with inhaled corticosteroids (ICS) for 3 months or greater
  • CT mucus score ≥ 5
  • Ability to tolerate study drug reflected by a post-treatment FEV1 ≥ 80% of pre- treatment, pre-bronchodilator FEV1

Who cannot take part

  • Adherence to study drug ≤ 70% after first treatment period
  • Current participation in an investigational drug trial
  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data
  • Other chronic pulmonary disorders, including (but not limited to) cystic fibrosis, chronic obstructive pulmonary disease, chronic bronchitis, vocal cord dysfunction (that is the sole cause of respiratory symptoms and at the PI's discretion), severe scoliosis or chest wall deformities that affect lung function, or congenital disorders of the lungs or airways
  • History of allergy or intolerance to study drug
  • Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study
  • Smoking of tobacco or other recreational inhalants in last year and/or >10 pack-year smoking history
  • Unwillingness to follow study procedures
  • Any other criteria that places the subject at unnecessary risk according to the judgment of the Principal Investigator

Where in United States

  • UCSF Airway Clinical Research CenterSan Francisco, United States

About the trial

What the trial wants to find out

This study evaluates 20% n-acetylcysteine (NAC) in the treatment of moderate-to-severe asthma that is complicated by mucus in the airway, as determined by CT imaging. The study is a crossover design, which means that half the study participants will get 20% NAC in the first 14-day treatment period and placebo in the next 14-day treatment period; and the other half will get placebo in the first 14-day treatment period and 20% NAC in the next 14-day treatment period.

The 2 groups in the trial

  • 20% n-acetylcystine (NAC)Treatment being tested

    Participants will self-administer nebulized 20% NAC (3 mL) and 2.5 mg albuterol inhalation solution (0.5 mL) 3 times per day for 14 days.

    Treatment: n-acetylcystine + albuterol

  • 0.9% salinePlacebo, for comparison

    Participants will self-administer nebulized 0.9% saline (3 mL) and 2.5 mg albuterol inhalation solution (0.5 mL) 3 times per day for 14 days.

    Treatment: 0.9% saline + albuterol

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
11 June 2026